SynthesisFrontiers in medicine2026
Retrospective analysis of primary extranodal unicentric Castleman disease: a systematic review.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unicentric Castleman disease of plasma cell type in the adrenal region: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Unicentric Castleman disease (UCD) is a rare lymphoproliferative disorder that typically occurs in lymph node-rich regions. Castleman disease originating in solid organs outside the lymph nodes is extremely rare. Current knowledge is limited to isolated case reports, leaving a lack of systematic evidence to guide diagnosis, management, and prognostic assessment. Methods: We conducted a systematic review of PubMed-reported cases and series of histologically confirmed of primary extranodal UCD over the past 20 years, summarizing their epidemiological, clinical, pathological, therapeutic features and outcome data. Results: A total of 99 cases from 83 publications were included. The median age at diagnosis was 44 years, with a male-to-female ratio of 0.77:1. The mean tumor size was 4.9 cm. The most frequent sites were the pancreas (14.1%), adrenal glands (14.1%), skeletal muscle (14.1%), parotid glands (13.1%), and kidneys (9.1%). Hyaline vascular type predominated (80.8%). Surgery was the primary treatment, yielding a 4-year recurrence-free survival rate of 84.6% (95% CI, 0.512-0.959). Lymphoma transformation occurred in 2% of cases. Radiotherapy and glucocorticoids may be effective treatment options. Conclusion: Primary extranodal UCD displays different anatomic origins but generally carries an excellent prognosis following complete surgical resection. Awareness of its potential for malignant transformation is essential for long-term management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.